Project Number GC-2012917 Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Year 2016 View Full Project Details for IND-enabling program and Phase 1 clinical trial for Yuma Therapeutics' novel and proprietary lead Hsp90 inhibitor, YT-83, for the treatment of Alzheimer's disease Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) i. Proteostasis/Proteinopathies Researcher and Organization Principal Investigator PERRELLA, YUKARI Principal Investigator First Name YUKARI Principal Investigator Last Name PERRELLA Awardee Organization YUMA THERAPEUTICS CORPORATION Awardee State Massachusetts Contact PI Country United States Project Detail Funding Opportunity Announcement PACT Program FY Overall Cost $556,174 Funding Organization Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Organization Country United States
